MUMBAI: As Israeli drugmaker Teva readies to acquire Allergan as part of its recent $40.5-billion deal, a large bounty of products is expected to be up for grabs for generic drugmakers.
According to collated data, products worth nearly $600 million may be needed to be divested as part of the anti-trust regulations of the US Federal Trade Commission. “In the next few weeks, the process may be initiated,” an investment banker told ET.
Help employers find you! Check out all the jobs and post your resume.
